A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs TRx 0237 (Primary)
  • Indications Dementia
  • Focus Registrational; Therapeutic Use
  • Sponsors TauRx Therapeutics
  • Most Recent Events

    • 22 Jul 2016 According to a TauRx Pharmaceuticals media release, the results from this study will be presented at the 10th International Conference on Frontotemporal Dementias (ICFTD).
    • 08 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Mar 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top